Dr. Anne Peters is one of our favorite endocrinologists in the limelight. She’s director of the Diabetes Program at the University of Southern California (USC), head of the nation’s largest outreach program for community-based diabetes prevention and treatment in Los Angeles, and author of the best-selling book Conquering Diabetes. She does a series of regular videos on diabetes for Medscape and other sites, and we’ve interviewed her and featured her here several times in the…Read more »
Today, we bring you more from the American Diabetes Association’s 73rd Scientific Sessions in Chicago, an update on the most interesting new drugs, and some stand-out research. (See also: yesterday’s big wrap-up.)
Two New Insulins and a Needle
Sanofi announced late-stage studies on its new investigational U-300 insulin showing that it’s as effective as their leading basal insulin on the market, Lantus, but with 21% fewer night-time low blood sugars.
At this point, the…
Sometimes, diabetes science confuses me.
Let’s take the news of an emerging class of diabetes drugs (type 2-focused) that apparently do something we’ve always thought was bad… but it’s actually not.
Sodium-glucose transporter (SGLT-2) inhibitors increase insulin production and effectiveness and stop the liver from producing too much glucose. Basically, they work by spilling glucose over into the urine which leads to less sugar in your bloodstream. The effect: lower BGs and A1Cs.
We’re officially conference-weary after running around the San Diego Convention Center for four days of ADA briefings, sessions, meet-ups and expo booth visits. We lugged home loads of material that will surely keep us post-happy here at the ‘Mine for weeks. So what was super-new and hot? Spoiler Alert: Not all that much this year.
Our overall impression was that a lot of cool technologies we’ve already seen are stuck in the holding pen while…